Kevin S. Boyle, Sr
2023
In 2023, Kevin S. Boyle, Sr earned a total compensation of $1.7M as Chief Executive Officer at ZIOPHARM Oncology, a 4% decrease compared to previous year.
Compensation breakdown
| Option Awards | $689,580 |
|---|---|
| Salary | $617,836 |
| Other | $409,529 |
| Total | $1,716,946 |
Boyle received $689.6K in option awards, accounting for 40% of the total pay in 2023.
Boyle also received $617.8K in salary and $409.5K in other compensation.
Rankings
In 2023, Kevin S. Boyle, Sr's compensation ranked 648th out of 2,918 executives tracked by ExecPay. In other words, Boyle earned more than 77.8% of executives.
| Classification | Ranking | Percentile |
|---|---|---|
All | 648 out of 2,918 | 78th |
Division Manufacturing | 364 out of 1,608 | 77th |
Major group Chemicals And Allied Products | 250 out of 901 | 72nd |
Industry group Drugs | 246 out of 864 | 72nd |
Industry Pharmaceutical Preparations | 158 out of 622 | 75th |
Source: SEC filing on April 26, 2024.
Boyle's colleagues
We found two more compensation records of executives who worked with Kevin S. Boyle, Sr at ZIOPHARM Oncology in 2023.